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Background: Infections occur in 30% of stroke patients and are associated with unfavorable outcomes. Preventive
antibiotic therapy lowers the infection rate after stroke, but the effect of preventive antibiotic treatment on functional
outcome in patients with stroke is unknown. The PASS is a multicenter, prospective, phase three, randomized,
open-label, blinded end-point (PROBE) trial of preventive antibiotic therapy in acute stroke. Patients are randomly
assigned to either ceftriaxone at a dose of 2 g, given every 24 h intravenously for 4 days, in addition to standard
stroke-unit care, or standard stroke-unit care without preventive antibiotic therapy. The aim of this study is to assess
whether preventive antibiotic treatment improves functional outcome at 3 months by preventing infections. This paper
presents in detail the statistical analysis plan (SAP) of the Preventive Antibiotics in Stroke Study (PASS) and was
submitted while the investigators were still blinded for all outcomes.
Results: The primary outcome is the score on the modified Rankin Scale (mRS), assessed by ordinal logistic regression
analysis according to a proportional odds model. Secondary analysis of the primary outcome is the score on the mRS
dichotomized as a favorable outcome (mRS 0 to 2) versus unfavorable outcome (mRS 3 to 6). Secondary outcome
measures are death rate at discharge and 3 months, infection rate during hospital admission, length of hospital
admission, volume of post-stroke care, use of antibiotics during hospital stay, quality-adjusted life years and costs.
Complications of treatment, serious adverse events (SAEs) and suspected unexpected serious adverse reactions
(SUSARs) are reported as safety outcomes.
Conclusions: The data from PASS will establish whether preventive antibiotic therapy in acute stroke improves
functional outcome by preventing infection and will be analyzed according to this pre-specified SAP.
Trial registration: Current controlled trials; ISRCTN66140176. Date of registration: 6 April 2010.
Keywords: stroke, infection, antibiotics, randomized clinical trial, statistical analysis planUpdate
Introduction
Stroke is a leading cause of death worldwide [1]. Infections
occur in 30% of stroke patients and are associated with
unfavorable outcomes [2,3]. Preventive antibiotic therapy
lowers infection rate in patients after stroke, but the effect* Correspondence: d.vandebeek@amc.uva.nl
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article, unless otherwise stated.of preventive antibiotic treatment on functional outcome
after stroke has not yet been investigated [4,5]. The Pre-
ventive Antibiotics in Stroke Study (PASS) is a phase three
randomized clinical trial investigating whether the pre-
ventive use of the antibiotic ceftriaxone improves func-
tional outcome in acute stroke patients by preventing
infections. We previously published the trial protocol and
an update of this protocol; we now present the statistical
analysis plan (SAP) [6,7]. This SAP was drafted without
knowledge of any of the outcomes by the investigators
and randomization code will not be broken before accept-
ance of the current paper for publication.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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PASS is a multicenter prospective, randomized, phase III,
open-label, blinded end-point superiority trial (PROBE) of
standard care with preventive ceftriaxone treatment com-
pared to standard care without preventive ceftriaxone. Adult
patients with stroke (both ischemic and hemorrhagic), a
score ≥1 on the National Institutes of Health Stroke Scale
(NIHSS) and stroke onset within 24 hours were included
[8]. Patients were excluded in case of infection at admission,
use of antibiotics within 24 hours before admission, previous
hypersensitivity or anaphylaxis to cephalosporins or penicil-
lin, subarachnoid hemorrhage, pregnancy or when death
seemed imminent. Patients were randomly assigned to
either ceftriaxone at a dose of 2 g, given every 24 h intraven-
ously for 4 days, in addition to stroke-unit care, or standard
stroke-unit care without preventive antibiotic therapy.
Randomization was performed through ALEA (online
software for randomized trials; https://nl.tenalea.net/amc/
ALEA/Login.aspx) and is based on a uniform distribution;
weight of the arms is equal (1:1). Randomization is stratified
according to study center (academic hospital, large non-
academic hospital, or small non-academic hospital) and
stroke severity (score on NIHSS 1 to 9 or >9) and per-
formed by using random blocks with a maximum block
size of 6; blocks of 2, 4 and 6 are made per stratum
combination [9]. The study has a PROBE design, which
implies that blinding is lost, but only as to treatment.
Patient and physician were aware of treatment alloca-
tion; however, the assessors of outcome were not. Data
were collected on admission, during hospital stay, and
at 3 months by standardized case record forms. The pri-
mary outcome is functional outcome at 3 months
follow-up, as assessed on the mRS during a structured
telephone interview by a trained assessor blinded for
treatment allocation. Secondary outcomes are death rate
at discharge and at 3 months, infection rate during hos-
pital admission, length of hospital admission, volume of
post-stroke care, use of antibiotics during hospital stay,
quality adjusted life years (QALYs) and costs. Safety out-
comes are complications of treatment, Serious adverse
events (SAEs) and suspected unexpected serious adverse
reactions (SUSARs). In the initial trial protocol, we pre-
sented a binary logistic regression analysis on the di-
chotomized mRS (0 to 2 versus 3 to 6) as primary
outcome, requiring a sample size of 3,200 patients, and
a proportional odds model in a secondary analysis of
the primary end point [9]. Blinded for any of the out-
comes, we have changed the primary analysis in PASS
from a binary logistic to an ordinal logistic regression
on the original mRS, enhancing statistical power. The
adapted power analysis showed that with identical as-
sumptions on the clinical effect, using a 0.05 two-sided
significance level and 80% study power, 2,550 patients
were needed [9]. The analysis of dichotomized mRS datawill now be the secondary analysis of the primary end
point.
On 23 March 2014, all patients were included and the
last follow-up is expected in June 2014. For the complete
study protocol and update, we refer to previous publica-
tions [6,7].
Protocol developments
PASS is registered at current controlled trials (www.con-
trolled-trials.com; ISRCTN: 66140176; date of registration:
6 April 2010). The medical-ethical board of the Academic
Medical Center, Amsterdam, approved the protocol on 5
May 2010, and 29 Dutch participating centers were added
in the course of the study. Due to the change in primary
analysis of primary outcome from a binary logistic ap-
proach to an ordinal logistic regression analysis and an ex-
pected rate of patients lost to follow-up and/or patients
with incomplete data of 5%, the total sample size was re-
duced from 3,200 patients to 2,550 patients in 2014 [7].
Importantly, no changes were made regarding the primary
outcome measurement (that is, the assumed size of the ef-
fect on the mRS). This update of the protocol was recently
published in this journal [7].
Statistical analysis plan
General analysis principles
The code of the database will not be broken until all effi-
cacy and safety data up to the last patient are included in
the database, after data verification and validation are
performed, and after the SAP has been accepted for publi-
cation. Analysis will be performed by the investigators of
the PASS study group (see Acknowledgements section)
assisted by a biostatistician of the Academic Medical
Centre in Amsterdam.
Patient flow diagram
The flow of participants will be displayed in the Consoli-
dated Standards of Reporting Trials (CONSORT) Flow
diagram (Figure 1). Due to the pragmatic design of the
study, the total number patients assessed for eligibility
has not been assessed.
Definition of intention-to-treat and per-protocol
population
Main analysis will be performed according to the intention
to treat (ITT) principle. The safety analysis will be per-
formed in a per protocol (PP) analysis. If a patient was by
fault randomized more than once, the first randomization
outcome was used. Patients who withdrew consent dir-
ectly after randomization (that is, before treatment was
initiated in those randomized for ceftriaxone in addition
to standard care, or within 6 hours after randomization in
those randomized for standard care) will be excluded from
analysis. Patients with protocol deviations in eligibility are
Figure 1 Flow-chart of patients.
Table 1 Number and type of protocol violations in
eligibility
Type of protocol
violation in eligibility
Ceftriaxone + standard care
(n =…)
Standard care
(n =…)
Age <18 years
Stroke
No neurological
symptoms (NIHSS = 0)
Onset of stroke >24
hours ago
Admission
Infection at admission
Use of antibiotics <24
hours before admission
Pregnancy
Known hypersensitivity
to cephalosporins
Previous anaphylaxis for
penicillin derivates
Subarachnoidal
hemorrhage
Death is imminent
Total number of
protocol violations in
eligibility
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(Table 1). Patients not receiving their allocated treat-
ment due to instantaneous crossover are considered
protocol violations; these patients will be included in
the ITT population. PP analysis will exclude patients for
whom protocol deviations in treatment and eligibility
were made (see protocol deviations in eligibility and
protocol deviations in treatment).
Handling of missing data
If outcome data could not be obtained at the 3 month
evaluation, we will first check the municipal council to
ensure that the patient is not deceased. All other patients
are considered lost to follow-up and will be tabulated, in-
cluding the percentage of missing outcome data and the
association with treatment. Missing outcome data will be
obtained by imputation, using the coefficients of five
rounds of imputation to obtain the final estimates. We will
perform sensitivity analysis. First, we will use single imput-
ation by last observation carried forward (LOCF). An ob-
server blinded for treatment allocation will obtain the last
observational score on the mRS using the medical charts
and the letters of discharge of the stroke episode. All pa-
tients with LOCF will be tabulated with an explanation for
the loss to follow-up (Table 2).
We will also perform a sensitivity analysis of baseline
characteristics of the group of patients not lost-to-follow-
Table 2 Assessment of follow-up by LOCF according to
treatment allocation
Patient number Explanation Treatment allocation
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will also perform a joint model analysis of the loss to
follow-up and the mRS change during follow-up [10].
Missing values of baseline characteristics will not be in-
cluded or imputed in the display of baseline characteris-
tics. When values are missing for dichotomous variables,
the actual denominator will be stated. In case of continu-
ous variables, a footnote will be added to show the num-
ber of patients for whom the variable was missing.
Protocol deviations in eligibility, consent procedure,
treatment
When a patient was randomized but did not adhere to in-
clusion or exclusion criteria, this was considered a proto-
col deviation regarding eligibility. Patients with protocol
deviations in eligibility were included in the ITT analysis,
but excluded from PP analysis.
In each center, the local investigator obtained written
informed consent from the patient or representative ac-
cording to the PASS study protocol. Patients who with-
drew consent directly after randomization were excluded
from further analysis. The flow of patients is displayed
in the CONSORT flowchart (Figure 1).
Treatment allocation was regarded as carried out ac-
cording to the study protocol when a patient random-
ized for ceftriaxone in addition to standard care received
ceftriaxone 2 gram each 24 hours for 4 days. Patients
were also considered as treated PP when treatment was
terminated within 4 days due to discharge, death, a pal-
liative care policy, an allergic reaction without anaphyl-
axis or a previous allergic reaction in medical history
(see inclusion and exclusion criteria and protocol devi-
ation in eligibility), other side effects of treatment, or
when treatment with ceftriaxone was changed into treat-
ment with another antibiotic because of an infection be-
cause these situations and what to do were all defined
and described in the initial protocol [6]. In patients allo-
cated to standard care, treatment was carried out ac-
cording to the study protocol when patients did not
receive preventive antibiotic therapy.
Baseline characteristics
Baseline characteristics of all patients will be outlined per
treatment allocation in a baseline table describing the fol-
lowing variables: age, sex, medical history (atrial fibrillation/
flutter, stroke, hypercholesterolemia, hypertension, myocar-
dial infarction, cardiac valve insufficiency/stenosis/replace-
ment, peripheral vascular disease, obstructive pulmonary
disease, and immunocompromised), current smoking, spe-
cific medication (anticoagulants, antiplatelet, statin, ACEinhibitor, ß-blocker, and proton pump inhibitor) prior to
stroke, disability prior to stroke on mRS, stroke severity on
NIHSS, performance of a screening test for swallowing
function, dysphagia, acute treatment (IV thrombolysis and
anticoagulant antagonist therapy) and diagnosis at dis-
charge (infarct, haemorrhage, TIA, or other). Outline of the
table is displayed in the ‘Outline of figures and tables’ sec-
tion (Table 3). All variables will be presented categorized by
treatment arm. Dichotomous variables will be displayed in
percentage with the number of patients divided by the total
number of evaluated patients. Continuous variables will be
reported as means with standard deviations when normally
distributed and in medians with interquartile ranges when
they do not meet the criterion of being normally distrib-
uted, as assessed by the Kolmogorov-Smirnov test. For con-
tinuous variables, the number of patients evaluated will be
presented in a footnote of Table 3.
Assessment of primary outcome
A structured telephone interview with each patient was
held at 3 months by one of three trained research nurses,
blinded for treatment allocation, to assess the primary
outcome on the mRS. This structured telephone interview
was validated in an earlier study [11].
Assessment of secondary outcomes
The assessment of secondary outcomes will be per-
formed as described below, for each outcome separately:
Infection rate during hospital admission
The total number of patients diagnosed with one or
more infection(s) during hospital admission will be re-
ported, as well as the total number of infections. Infec-
tions will be reported according to subtypes pneumonia,
urinary tract infection and other infection. Infection will
be assessed in two ways. First, the infection will be diag-
nosed in the clinical setting by the treating physician
and registered as pneumonia, urinary tract infection or
other infection. The clinical diagnosis of infection will
be used for the primary analysis. Suspected infections
without diagnostics being performed are also recorded
and reported as such (for example, in a patient with a
palliative care policy). Second, infection will be catego-
rized by two infectious disease specialists who are
blinded for treatment allocation, using the modified cri-
teria of the Centers for Disease Control and Prevention
(CDC criteria) [12]. For this second categorization, pa-
tients with fever, new onset delirium or clinical diagnosis
of infection during hospital admission will be reviewed.
For this purpose, data on the diagnostic procedures dur-
ing admission as recorded in the Case Record Form
(CRF) will be used. For the diagnosis of pneumonia and
urinary tract infection prespecified algorithms will be
used based on the CDC-criteria (Figures 2 and 3).
Table 3 Baseline characteristics
Baseline characteristics Ceftriaxone +
standard care
Standard
care
Age - years
Male sex - % n/N
Medical history - % n/N
- Atrial fibrillation/flutter
- Stroke
- Hypercholesterolemia
- Hypertension
- Myocardial infarction
- Cardiac valve insufficiency/stenosis/
replacement
- Peripheral vascular disease
- Obstructive pulmonary disease
- Immunocompromised
Current smoker - % n/N
Medication prior to stroke - % n/N
- Anticoagulants
- Antiplatelet
- Statin
- ACE inhibitor
- Bèta-blocker
- Proton pump inhibitor
Disability prior to stroke - mRS *
Stroke severity - NIHSS **
Swallowing screening performed - %
n/N
Dysphagic patients - % n/N
Acute treatment - % n/N
- IV thrombolysis
- Coagulant therapy
Diagnosis at discharge - % n/N
- Infarction
- Hemorrhage
- Transient ischemic attack (TIA)
- Other
*mRS, denotes modified Rankin Scale.
**NIHSS denotes National Institutes of Health Stroke Scale.
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ture from the presumed site of infection, other than the
lungs or urine, with a clinically relevant pathogen will be
diagnosed as ‘other infection.’ Patients will be catego-
rized as having confirmed pneumonia, urinary tract in-
fection, or other infection. Only bacterial infections will
be assessed since preventive antibiotic therapy aims to
reduce these infections. Infection with Clostridium diffi-
cile is reported as a treatment complication. Case defin-
ition of this infection is diarrhea plus a positive C.difficile toxin test. Clostridium infection was diagnosed
by the treating physician and was reviewed by the expert
panel.
Death rate at discharge and at 3 months
Death during hospital admission was recorded in the
CRF by the treating physician and notified as an SAE to
the trial office. Death was also registered at the 3 months
follow-up. If needed, survival status at 3 months was
evaluated through contact with general practitioners and
the municipality register.
Length of hospital stay
The day of admission and discharge was recorded in the
CRF by the treating physician. Length of hospital admis-
sion is measured in days.
Total use of antibiotics during hospital stay
The use of antibiotics other than preventive antibiotic
therapy will be recorded in the case record form. Total
antibiotic use will be recorded in units of the ‘defined
daily dose’ (DDD) and the number of days of use. For
definitions of the DDD, classification according to the
World Health Organization (WHO) will be used for
each antibiotic [13].
Volume of post-stroke care, cost-effectiveness analysis
The cost-effectiveness will be measured by an economic
analysis conducted alongside the study. This analysis is
not included in the publication to which this analysis
plan applies.
Assessment of safety outcomes
Safety outcomes are complications of treatment, SAEs
and SUSARs. All SAEs and SUSARs during the hospital
stay are recorded in case record forms by the treating
physician and reported to the trial office. SAEs and SUS-
ARs occurring after discharge are recorded during the
follow-up interview at 3 months. The physician records
treatment complications in the CRF (diarrhea caused by
C. difficile, allergic reaction that caused cessation of cef-
triaxone, infection with ceftriaxone resistant micro-
organism, phlebitis at place of IV-catheter, elevation of
liver enzymes, oliguria or elevation of serum creatinine).
Cause of death will be reviewed by two independent
observers. They will use information from the hospital
discharge letter or the medical correspondence received
by the general practitioner in case the patient died after
discharge. Discrepancies will be reviewed in a consensus
meeting in the presence of a third investigator. Outcome
parameters were derived from three recent cardiovascu-
lar trials and were modified for expected outcomes in
our study [14-16]. A distinction will be made among a
cardiovascular cause (brain infarction, brain hemorrhage,
Figure 2 Diagnosis of pneumonia.
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vascular cause), an infection (pneumonia, sepsis or an-
other infection), death by any type of malignancy, death
by any other cause (for example, traffic accident), with-
drawal of treatment due to a poor prognosis or un-
known cause of death.
Analysis of primary outcome
An ordinal regression model on the total range of the
mRS will be performed as the first analysis of primary
outcome, under the assumption of proportional odds
[7]. The distribution of primary outcome (for example,
functional outcome on the mRS) in both treatment
groups will be expressed in a histogram (Figure 4). Both
adjusted and unadjusted analyses will be performed and
reported. In clinical trials, adjusting for prognostic co-
variates improves statistical power, can correct for im-
balances in baseline prognostic variables and can reduce
variability in data [17,18]. The choice of prognostic co-
variates is mostly based on imbalances across treatment
groups, prognostic factors that are related to the primary
outcome, or a combination of both [17]. As the investi-
gators are blinded for all outcome data until the statis-
tical analysis plan is accepted for publication, we chose
to use the most important prognostic factors for out-
come after stroke: age, stroke severity on the NIHSS,
history of stroke, history of diabetes, prior disability as
defined on mRS, and stroke type [19]. Stratification of
randomization was performed according to both study
center and stroke severity, so we will also include study
center as a covariate. The second analysis of the primary
endpoint, that is, the dichotomized score on the mRS
(for example, favorable versus unfavorable, mRS 0 to 2
versus mRS 3 to 6), will be expressed as OR with 95%Figure 3 Diagnosis of urinary tract infection.confidence intervals (CI; Table 4). Results of the dichoto-
mized approach will be compared to the results of the
primary analysis of primary outcome.
Analysis of secondary outcomes
The number of patients with one or more in-hospital post-
stroke infection(s) will be presented as numbers with event
of numbers evaluated and analyzed using the chi-square
test, and OR estimates with 95% CI. Infection rates will be
reported as ‘judged by treating physicians’ and ‘infectious
diseases panel.’ Death rate at discharge and at 3 months will
also be analyzed using the chi-squared test and presented
as OR estimates and 95% CI. Use of antibiotics in defined
daily doses and length of hospital admission will be ana-
lyzed using the two group t-test or Mann- Whitney test
where appropriate (Table 4). The analysis of volume of
post-stroke care, use of antibiotics during 3 months follow-
up and the cost-effectiveness analysis will be analyzed using
a separate analysis protocol and presented in a subsequent
paper and is, therefore, not discussed here.
Safety outcomes
Complications of treatment, SAE’s and SUSAR’s per pa-
tient will be tabulated according to treatment group, and
analyzed using the chi-squared test (Table 5 and table 6).
Subgroup analysis of primary and secondary outcomes
We will perform the following sub-group analyses for the
primary outcome: stroke type (infarction or hemorrhage),
stroke severity (NIHSS 1 to 9 or NIHSS 10 to 30), time be-
tween stroke symptoms and start of the antibiotic treat-
ment (0 to 12 h versus 12 to 24 h) and age. For the
subgroup analysis of primary analysis of primary outcome,
the single OR from the proportional odds model will be
Figure 4 Graphic display of primary outcome.
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analysis of secondary analysis of primary outcome, we will
tabulate the results and analyze them using the chi-
squared test and presented as OR and 95% CI ((Table 7:
subgroup analysis of primary outcome). In addition to
these predefined subgroup analyses, we will perform a lar-
ger set of exploratory additional analyses. For secondary
outcomes, we will perform all the previous mentioned
subgroup analyses (stroke type, severity, time to treat-
ment, and age). In addition we will perform analysis on
presence of a swallowing disorder, respiratory tract infec-
tions, and a urinary catheter.
Authorships
Two PhD students (WFW and J-DV) of this project will
share first authorship; the two principle investigators (PIs)
of this project will share last authorship (DvdB and PJN;Table 4 Secondary outcomes
Ceftriaxone + stan
Secondary analysis of primary outcome
Favorable outcome - % n/N
Secondary outcomes:
Clinical diagnosis of infection during admission – n
- Pneumonia
- Urinary tract infection
- Other
Diagnosis of infection based on expert panel - n
- Pneumonia
- Urinary tract infection
- Other
Mortality - % n/N
- At discharge
- At 3 months
Length of hospital stay - days
NA, not applicable.DvdB corresponding author); local investigators who in-
cluded at least 100 patients will be co-author; PASS study
group members and physicians in expert panels for
outcome-scoring will be co-author; and all local investiga-
tors who included less than 100 patients in PASS will be
explicitly listed in the PASS investigators list.Discussion
The aim of our study is to investigate whether preventive
antibiotic therapy improves functional outcome by redu-
cing the number of infections in acute stroke patients.
With this SAP, we present the analyses that will be pub-
lished in the primary publication. By publishing the statis-
tical analysis plan before knowledge of any outcome, we
stimulate transparency of scientific conduct and allow
others to add timely suggestions for additional analyses.dard care (n =…) Standard care (n =…) P OR 95% CI
NA
Table 5 Number and type of serious adverse events
Type of SAE* -%
n/N
Ceftriaxone + standard care
(n =…)
Standard care
(n =…)
P
- Death
- Life-threatening
event
- New hospitalization
- Prolongation of
existing
hospitalization
- Persistence of
significant disability
or incapacity
Total number of
SAE’s
*SAE, serious adverse event.
Table 7 Subgroup analysis of primary outcome
Ceftriaxone + standard
care (n =…)
Standard care
(n =…)
P OR
95% CI
Favorable
outcome (mRS*
0 to 2) - % n/N
- Ischemic stroke
- Hemorrhagic
stroke
- Transient
ischemic attack
(TIA)
- Other
Favorable
outcome (mRS 0
to 2) - % n/N
- NIHSS** 1 to 9
- NIHSS 10 to 30
Favorable
outcome (mRS 0
to 2) - % n/N
- time to
treatment 0 to
6 h
- time to
treatment 6 to
12 h
- time to
treatment 12
to 24 h
*mRS, denotes modified Rankin Scale.
**NIHSS denotes National Institutes of Health Stroke Scale.
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fections. A systematic review and meta-analysis of 87
studies showed that infections complicate stroke in 30%
of all stroke patients. Pneumonia was associated with
mortality with an OR of 3.62 (95% CI 2.80 to 4.68) [3].
The effect of preventive antibiotic therapy on outcome
in stroke patients has been investigated in few studies.
Two meta-analyses of these studies showed that prevent-
ive antibiotic therapy reduced the number of infections
[4,5]. The proportion of patients who died and the num-
ber of disabled patients were not significantly reduced,
but numbers of included patients were small.
The PROBE design with open-label preventive antibiotics
might introduce detection bias for infection. Physicians are
aware of the treatment allocation, which potentially influ-
ences decisions on nonscheduled treatment (that is, the de-
tection and treatment of patients with infection). This
might influence the outcome measure of infection rate. To
control for this bias, we will provide a secondary judgementTable 6 Complications of treatment
Adverse
reaction - % n/N
Ceftriaxone + standard care
(n =…)
Standard care
(n =…)
P
- Diarrhea caused by
C. difficile
- Allergic reaction
that caused
cessation of
ceftriaxone
- Infection with
ceftriaxone-resistant
microorganism
- Phlebitis at place of
IV-catheter
- Elevation of liver
enzymes
- Oliguria or
elevation of serum
creatinine
Total number of adverse reactions - number %.of infection diagnosis by a blinded expert panel, according
to CDC criteria. The CDC criteria are restrictive and use
ancillary investigations such as blood tests, chest X-rays
and culture results to confirm the diagnosis of infection. In
clinical practice, for a stroke patient with fever, a cough and
abnormalities on auscultation, a physician will often not
wait for culture results or refrain from treating pneumonia
when a chest X-ray does not (yet) show a consolidation.
Preventive treatment with ceftriaxone after stroke might
improve outcome by preventing infections. A potential
beneficial effect on functional outcome might be caused
by a direct effect of prevention of infections in patients
after stroke, most commonly pneumonia, but also by the
result of decreased length of stay on the stroke unit of
even in the hospital. A recent study of individual patient
data in a meta-analysis of randomized trials of ventilator-
associated pneumonia prevention showed that an overall
attributable mortality of ventilator-associated pneumonia
is 13%, which was mainly caused by prolonged exposure
to the risk of dying due to increased length of ICU stay
[20]. Ceftriaxone also has neuroprotective properties, at
least in animal studies of stroke, which may be mediated
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transporter [21].
Antibiotics may induce overgrowth of antibiotic resist-
ant pathogens in individual patients [22]. In the general
population, selective antibiotic pressure is an important
determinant of emergence and dissemination of antibiotic
resistance [23,24]. Previous clinical trials on preventive
antibiotic therapy in stroke, antibiotic resistance patterns
of bacteria cultured from patients with or without pre-
ventive antibiotics were similar, but numbers of patients
were low [25]. Previous work has showed that implemen-
tation of preventive antibiotics in the ICU did not increase
resistance rates in an environment with low levels of anti-
biotic resistance [26]. We will compare total antibiotic use
in both treatment groups during hospital stay and collect
stool specimens in a nested case control study that in-
cludes 300 patients.
During the course of the study we changed the analysis
of primary outcome on the mRS from a dichotomized
analysis toward an ordinal regression analysis. The ordinal
regression analysis is increasingly used in stroke trials be-
cause of its higher efficiency [27]. Importantly, our pri-
mary outcome (for example, functional outcome on the
mRS) was not changed, and the assumptions used in the
initial sample size calculation were maintained. By using
ordinal regression analysis, the total sample size was low-
ered from 3,200 patients to 2,550 patients. Using this
method enables us to reduce the number of patients with-
out changing the assumptions on the magnitude of the ef-
fect on the primary outcome scale from the original
sample size calculation.
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